EAM Investors’s Avalo Therapeutics AVTX Stock Holding History

EAM Investors’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-39	Closed	-$605K	–	238
2019 Q2	$605K	Hold	39	–	–	0.15%	234
2019 Q1	$653K	Buy	+39	New	+$583K	0.16%	232

Other funds holding AVTX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

EAM Investors's AVTX Position: Q3 2019 in Review

EAM Investors sold out of Avalo Therapeutics (AVTX) in Q3 2019, closing a stake of 39 shares — an estimated $605K sold.

EAM Investors first reported a position in AVTX in Q1 2019 and held it in 2 quarters. The position peaked at $653K in Q1 2019. 36 funds tracked by Wall St. Rank hold AVTX as of Q3 2019.

EAM Investors reported no remaining Avalo Therapeutics position as of Q3 2019 after selling out during the quarter.
EAM Investors sold 39 Avalo Therapeutics shares in Q3 2019, an estimated $605K.
EAM Investors first reported a position in Avalo Therapeutics in Q1 2019 and held it in 2 quarters.
EAM Investors's Avalo Therapeutics position peaked at $653K in Q1 2019.
36 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2019.

Based on EAM Investors's 13F filing for Q3 2019, filed 13 Nov 2019.